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Fullerenes are carbon cages of variable size that can be derivatized with various side chain 
moieties resulting in compounds that are being developed into nanomedicines. Although 
fullerene use in several preclinical in vitro and in vivo models of disease has demonstrated their 
potential as diagnostic and therapeutic agents, little is known about how they enter cells, what 
organelles they target, and the time course for their cellular deposition. Fullerenes (C70) that have 
already been shown to be potent inhibitors of mast cell (MC)–mediated allergic inflammation 
were conjugated with Texas red (TR) and used in conjunction with confocal microscopy to 
determine mechanisms of uptake, the organelle localization, and the duration they can be 
detected in situ. We show that C70-TR are nonspecifically endocytosed into MCs, where they are 
shuttled throughout the cytoplasm, lysosomes, mitochondria, and into endoplasmic reticulum at 
different times. No nuclear or secretory granule localization was observed. The C70-TR remained 
detectable within cells at 1 week. These studies show that MCs endocytose fullerenes, where 
they are shuttled to organelles involved with calcium and reactive oxygen species production, 
which may explain their efficacy as cellular inhibitors. 
 
From the Clinical Editor: Fullerenes are carbon cages of variable size that have already been 
shown to be potent inhibitors of mast cell (MC)-mediated allergic inflammation. These were 
conjugated with Texas red (TR) and used in conjunction with confocal microscopy to determine 
mechanisms of uptake, the organelle localization, and duration, demonstrating that MCs 
endocytose fullerenes, which are shuttled to organelles involved with calcium and reactive 
oxygen species production. This intracellulac trafficking may explain the efficacy of fullerenes 
as cellular inhibitors. 
 




The use of nanomaterials to diagnose and treat disease has been a goal for scientists ever since 
the advent of methods to manipulate molecules at the nanometer level. Fullerenes are one type of 
nanomaterial that are being investigated for diagnostic and therapeutic modalities.1 Our studies 
have already suggested that certain derivatives possess anti-inflammation properties,2, 3 and other 
groups have demonstrated their use in neurological disorders.4 We additionally showed that 
certain fullerenes could potentiate hair growth.5 However, their use as new nanomedicines has 
not yet fully been realized because of the lack of clearly identified candidates for a particular 
disease. Once these candidates are more thoroughly characterized, relevant pharmacological 
and biodistribution data must be assessed. Fullerenes' full capabilities as new nanomedicines has 
been additionally hampered by the inconsistency in how the water-insoluble fullerenes are 
derivatized into biologically acceptable agents; most studies thus far have used highly impure 
and uncharacterized material, which makes interpretation of data difficult. 
 
To begin to address the issue of in situ biodistribution, earlier characterized fullerene derivatives 
that have been shown to have anti-inflammatory activity3 were modified by chemically adding 
reporter dyes. Using this technique we were able to study the cellular uptake and distribution of 
fullerenes using a human mast cell (MC) model. It is shown that these fullerene derivatives are 
endocytosed into the cell and trafficked to different organelles at different time points. The 
fullerene conjugate localized with a particular predominance to calcium and reactive oxygen 







All fullerene derivatives were synthesized at Luna Innovations Inc. Texas red (TR) was attached 
to the functionalized 70-carbon fullerene (C70), earlier shown to demonstrate anti-inflammatory 
properties,3 as shown in Supplementary Figure S1 (available in the online version of this article). 
Monoprotected octa(ethyleneglycol)diamine (Supplementary Figure S1, step 1, available in the 
online version of this article) (1 mmol) was reacted with ethylmalonylchloride (1 mmol) in the 
presence of triethylamine (1.2 mmol) in anhydrous dichloromethane (DCM, 30 mL) for 3 hours 
at 23°C, and the mixture was washed twice with brine before subjecting it to column 
chromatographic purification (silica gel). The isolated oily product (Supplementary Figure S1, 
step 2, available in the online version of this article) was characterized by both proton nuclear 
magnetic resonance (1H-NMR) and 13C-NMR. Malonamide 2 (10 μmol) was reacted with one 
equivalent of iodine, 2.3 equivalents of 1,8-diazabicycloundec-7-ene, and 1.0 equivalent of the 
C70 monoadduct (Supplementary Figure S1, step 3, available in the online version of this article), 
which was prepared from C70and di(dodecyl)lmalonate under Bingel conditions (reaction to 
create extensions to the fullerene sphere). The reaction mixture was stirred for 4 hours in toluene, 
washed with brine, and concentrated for silica column purification. The isolated red band from 
silica column, characterized by both NMR and matrix-assisted laser desorption-ionization mass 
spectrometry (MALDI-MS), was treated with 20% trifluoroacetic acid in DCM for 2 hours, and 
the solvent was evaporated using a rotary evaporator and pumped under vacuum for 6 hours. The 
resulting amine-functionalized C70 bisadduct (Supplementary Figure S1, step 4, available in the 
online version of this article) (10 mg) in its trifluoroacetic acid salt form was dissolved in 5 
mL dimethylformamide (DMF) and stirred with two equivalents of triethylamine for 10 minutes. 
Next, 2 mg of TR N-hydroxysuccinimide ester (Biotium, Inc., Hayward, California) dissolved in 
0.2 mL amine-free DMF (Sigma Aldrich, Milwaukee, Wisconsin). was added to the mixture and 
stirred for 6 hours at room temperature. DMF was removed under vacuum, and the residue was 
subjected to preparative thin-layer chromatography (silica phase) for purification. After the thin-
layer chromatography plate was spotted with the residue, it was eluted with a mixture of DCM 
and methanol. There were three bands: trace amounts of the dye on the top, product 
(Supplementary Figure S1, step 5, available in the online version of this article) in the middle, 
and unreacted C70 (Supplementary Figure S1, step 4, available in the online version of this 
article) at the bottom. The plate was dried in a hood. The product band was scraped off the plate, 
redissolved in a mixture of methanol and DCM (1:1), filtered and concentrated to dryness, 
yielding pure 70-carbon fullerene-TR (C70-TR) conjugate, which was characterized by MALDI-
MS, ultraviolet-visible, and fluorescence spectrometry. 
 
Human mast cell cultures and addition of fullerene derivatives 
 
Human skin was received from the Cooperative Human Tissue Network. All studies were 
approved by their Human Studies Institutional Review Board. Tryptase-chymase positive MCs 
(MCTC) type6 were purified and cultured as described,7, 8, 9 MCs were incubated with 5 μg/mL of 
C70-TR in normal medium for 5 hours, washed, and photodocumented, or placed back in culture 
for up to 1 week at 37°C in a 6% CO2 incubator. Preliminary experiments demonstrated that the 
C70-TR was maximally taken up within the MCs at 5 hours; longer incubation times did not 
increase fullerene uptake. Thus, this time point was used in all subsequent experiments. 
 
Endocytosis studies of fullerene derivatives 
 
To determine the mechanisms of fullerene uptake MCs were first pretreated with or without 
various inhibitors of cellular uptake (10 μg/mL each of filipin, inhibitor of the raft/caveolae 
endocytosis pathway; amiloride, inhibitor of clathrin-independent pathways; and indomethacin, 
inhibitor of caveolae pathways). Cells were incubated for 30 minutes at 37°C in a humidified 
atmosphere with 6% CO2, washed, and the fullerenes added for 5 hours before being washed and 




Mast cells were incubated with C70-TR for 5 hours, washed, and incubated with the indicated 
organelle-specific dyes (Mito-Tracker, Lyso-Tracker, and ER-Tracker; Invitrogen, Carlsbad, 
California) for the final 30 minutes. In some experiments cells were treated as above and 
cytospins prepared at various times after washing. The MC-specific antibody, G3 (ref. 10), 
attached to fluorescein isothiocyanate, was used to examine secretory granule co-localization. 
Cells were visualized using a Yokogawa multiple-lens Nipkow spinning-disk scanner (CSU10) 
(Perkin-Elmer Laboratories, Waltham, Massachusetts) illuminated by a ∼100-mW krypton/argon 
laser mounted to a Nikon TE2000U inverted confocal microscope (Nikon Instruments, Inc., 
Melville, New York). Images were captured using a Hamamatsu Orca ER (Hamamatsu 
Photonics, Bridgewater, New Jersey) and SimplePCI software (Hamamatsu Corp., Sewickley, 
Pennsylvania). 
 
Calcium and ROS measurement 
 
MCs were pretreated with or without C70-TR overnight, washed with Tyrodes buffer 
supplemented with bovine serum albumin, and incubated with Fura-2 AM (2 μM; Invitrogen) for 
30 minutes at 37°C. Cells were washed, stimulated with an FcɛRI activator (3B4), and calcium 
flux measured in real time on a Perkin-Elmer LS55 Spectrofluorometer (Perkin-Elmer 
Laboratories). For ROS production cells were exposed to fullerenes as above. After washing, 
cells were resuspended in normal medium containing 5 μM dichlorodihydrofluorescein2 at 37°C 
for 30 minutes, washed, and FcɛRI activation-induced changes in mean fluorescence measured 
using spectroscopy with excitation at 502 nm and emissions at 523 nm for 15 minutes. The data 
are presented as fluorescence intensity of the 523-nm emission over time. All experiments were 
performed in triplicate, and degranulation was measured in parallel. Separate experiments were 




Design and synthesis of dye-conjugated fullerenes 
 
A C70-based fullerene was selected for dye conjugation that is similar in structure to those 
determined to be potent anti-inflammatories and inhibitors of FcɛRI-mediator release from 
MCs.3 The strategy for designing this C70-TR dye conjugate is shown stepwise in Supplementary 
Figure S1. Dye conjugation to the fullerene compound was confirmed by MALDI-MS and 
absorption spectra (data not shown). All free, unconjugated dye was dialyzed to separate from 
the C70-TR conjugate. 
 
Fullerenes enter MCs through endocytosis 
 
Little is known about how fullerenes enter cells and where fullerenes localize in situ. To examine 
the mechanisms of cellular entry we preincubated MCs with several broad-acting endocytosis 
inhibitors and examined for fullerene localization within cells. In general, no fullerene 
localization was observed when cells were pretreated with the endocytosis inhibitors filipin and 
amiloride (Figure 1). The use of other endocytosis inhibitors such as indomethacin demonstrated 
a similar lack of fullerene uptake, which was not affected by higher fullerene concentrations or 
extended incubation times (not shown). Thus, fullerenes are taken up by human MCs through an 
endocytosis pathway. 
 
Intracellular trafficking of C70-TR 
 
Time course studies were performed to determine the localization of the fullerenes in human 
MCs. As seen in Figure 2, A–F the majority of the C70-TR was observed in the endoplasmic 
reticulum (ER) and lysosomes at 4 hours after washout (9 hours total). Minimal co-localization 
was observed within the mitochondria (Figure 2, G–I) at this time point. Similar localization was 
observed at 24 and 96 hours after washout with less co-localization within the lysosomes 
(Figures 3, A–F and 4, A–F). The fullerenes were detected up to 1 week within the cells, 
although there was notably less C70-TR within the cell (Figure 5, A–F). As with earlier time 
points there was a predominance of fullerene localization with the ER. The presence of the 
fullerenes in the cells at any of the times examined did not affect cell viability, which was 
consistently greater than 90% and not significantly different compared to nontreated cells (not 
shown). This suggests that fullerenes are not quickly shuttled out of the cell but persist within 
organelles involved in FcɛRI-dependent mediator release. 
 
 
Figure 1. Endocytosis inhibitors block fullerene entry into cells. Skin mast cells were incubated with or without the 
indicated endocytosis inhibitors for 16 hours in the tissue culture incubator. The next day cells were incubated with 
the Texas red–conjugated C70 fullerenes for 5 hours, washed, and analyzed by confocal microscopy. Pictures (63× 
oil; cropped as needed) are representative of two separate experiments. 
 
C70-TR fullerene co-localized in ER reduces calcium release and ROS production 
 
The activation of MC FcɛRI leading to degranulation is calcium-dependent and induces elevated 
cellular levels of ROS.11, 12 Given that calcium and ROS are produced within the ER and 
mitochondria, and we and others have demonstrated that these organelles accumulate fullerenes 
with varying affinities, we hypothesized that the co-localization of fullerene derivatives 
developed herein would inhibit these cellular mediators. The intracellular calcium and ROS 
levels in FcɛRI-challenged cells with or without preincubation with fullerenes were measured to 
determine the impact that this fullerene has on both calcium stores and ROS levels. As seen 
in Figure 6, the C70-TR inhibited calcium (Figure 6, A, B) and ROS levels (Figure 6, C, D) as 
compared with the untreated MC control. In general, a higher inhibition of release of intracellular 
calcium stores occurred as compared with ROS levels. 
 
 
Figure 2. Time course of organelle localization using Texas red–conjugated C70 (C70-TR) fullerenes in human mast 
cells (MCs). Cells were incubated with C70-TR fullerenes (5 μg/mL) for 5 hours, washed, and returned to culture for 
the indicated times: Figure 2, 4 hours; Figure 3, 24 hours; Figure 4, 96 hours; Figure 5, 1 week. For the final 30 
minutes cells were incubated with (A–C) ER-Tracker (500 nM), (D,E)Lyso-Tracker (25 nM), or (F–H) Mito-
Tracker (20 nM), washed, placed on a coverslip, and imaged using confocal microscopy. Pictures (63× oil; cropped 




Figure 3. Time course of organelle localization using Texas red–conjugated C70 (C70-TR) fullerenes in human mast 
cells (MCs). Cells were incubated with C70-TR fullerenes (5 μg/mL) for 5 hours, washed, and returned to culture for 
the indicated times: Figure 2, 4 hours; Figure 3, 24 hours; Figure 4, 96 hours; Figure 5, 1 week. For the final 30 
minutes cells were incubated with (A–C) ER-Tracker (500 nM), (D,E)Lyso-Tracker (25 nM), or (F–H) Mito-
Tracker (20 nM), washed, placed on a coverslip, and imaged using confocal microscopy. Pictures (63× oil; cropped 
as needed) representative of two separate MC cultures. 
 
Figure 4. Time course of organelle localization using Texas red–conjugated C70 (C70-TR) fullerenes in human mast 
cells (MCs). Cells were incubated with C70-TR fullerenes (5 μg/mL) for 5 hours, washed, and returned to culture for 
the indicated times: Figure 2, Figure 4 hours; Figure 3, 24 hours; Figure 4, 96 hours; Figure 5, 1 week. For the final 
30 minutes cells were incubated with (A–C) ER-Tracker (500 nM), (D,E) Lyso-Tracker (25 nM), or (F–H) Mito-
Tracker (20 nM), washed, placed on a coverslip, and imaged using confocal microscopy. Pictures (63× oil; cropped 
as needed) representative of two separate MC cultures. 
 
 
Figure 5. Time course of organelle localization using Texas red–conjugated C70 (C70-TR) fullerenes in human mast 
cells (MCs). Cells were incubated with C70-TR fullerenes (5 μg/mL) for 5 hours, washed, and returned to culture for 
the indicated times: Figure 2, 4 hours; Figure 3, 24 hours; Figure 4, 96 hours; Figure 5, 1 week. For the final 30 
minutes cells were incubated with (A–C) ER-Tracker (500 nM), (D,E)Lyso-Tracker (25 nM), or (F–H) Mito-
Tracker (20 nM), washed, placed on a coverslip, and imaged using confocal microscopy. Pictures (63× oil; cropped 
as needed) representative of two separate MC cultures. 
 
Figure 6. Texas red–conjugated C70 (C70-TR) fullerenes co-localized in endoplasmic reticulum reduce calcium 
release and reactive oxygen species (ROS) production. FcɛRI stimulation (3B4; 1 μg/mL) of fullerene-treated cells 
(20 μg/mL) was examined in parallel for calcium stores release as determined by the ratio 340 nm/380 nm and ROS 
measured by dichlorodihydrofluorescein detection. Results show average value (±SD) from at least three separate 




These are to our knowledge the first studies examining fullerene trafficking within human MCs. 
It was observed that the C70-TR conjugated fullerenes were taken up through an endocytosis-
dependent mechanism and persisted in the MCs for up to 1 week. The intracellular localization 
was found predominantly in the ER and to a lesser degree in mitochondria and lysosomes. No 
fullerenes were detected in the tryptase-containing secretory granules or in the nucleus at any 
time points measured. Taken together, it is clear that MCs actively take up fullerenes through an 
endocytotic pathway, where they remain mostly localized to ER and to a lesser extent in 
lysosomes and mitochondria. 
 
The ER is the site for synthesizing and ensuring proper folding of proteins within a cell and 
shuttles misfolded proteins through a degradative pathway. Recent evidence suggests that this 
process involves the formation of disulfide bonds that stabilize the folding of nascent proteins 
resulting in an oxidizing environment and ROS generation.13 In addition to the ER, mitochondria 
also produce ROS due to the production of adenosine triphosphate following oxidative 
phosphorylation. Our results using C70-based derivatives are consistent with several publications 
examining fullerene localization in different cell types, in which deposition in different 
intracellular organelles depends on the moieties added to the carbon cage.2, 14, 15, 16, 17 For 
example, C63(COOH)6 or C61(CO2H)2 seem to localize to mitochondria,14, 16 whereas C60 
mixtures dispersed in tetrahydrofuran (and not purified from this solvent) localize to lysosomes 
and nuclei in macrophages.17 Our results are also consistent with earlier studies suggesting 
fullerenes can easily penetrate into a lipid membrane, where they induce nontoxic changes in the 
structural and elastic properties of the lipid bilayer at very high concentrations.18 Taken together, 
fullerenes as a general class have a varied localization profile within cells; how the fullerene 
cage is modified determines where the cage localizes in situ. Given that no fullerene formulation 
has yet been identified for treating a particular disease, it is difficult to extrapolate in situ 
localization results from different fullerene preparations. 
 
The results demonstrating that C70-based fullerenes are endocytosed and localize to ER differ 
from earlier published results showing that endocytosed C60-based fullerenes localize to the 
mitochondria and lysosomes.19, 20 The ER accumulation of C70-based fullerenes explains the data 
shown that preincubation of MCs with the same fullerenes caused a reduction of FCɛRI-
mediated calcium release and ROS generation. These findings may help explain fullerenes' 
mechanism of inhibition of FcɛRI-activated mediator release from MCs.2 The release of calcium 
stores and production of ROS occur in these organelles21; although release of calcium stores is 
absolutely required for FcɛRI-mediator release, it is still not clear if increased ROS levels 
parallel mediator release or are a consequence of FcɛRI crosslinking. Calcium stores release 
from the ER in response to FcɛRI crosslinking is controlled by inositol 1,4,5-trisphosphate. Thus, 
the observation that fullerenes localize to this organelle fits well with our data showing that 
calcium stores release and ROS production are inhibited when FcɛRI-challenged MCs are 
prechallenged with fullerenes. Current efforts are aimed at determining what ER-associated 
signaling molecules(if any) are bound to fullerenes, which would help explain how these 
molecules exert their inhibitory activities. 
 
Fullerenes were also consistently found (but to a lesser extent as compared to ER accumulation) 
in lysosomes. Endocytosis from the plasma membrane can occur by a variety of mechanisms, 
and once uptake occurs the molecules are then routed through lysosomes to various places within 
cells. We observed lysosomal accumulation of C70-TR predominantly at 4 hours, 96 hours, and 1 
week after washout, perhaps indicating the cells shuffling the conjugates from the membrane 
early and to the membrane for possible excretion at the later times. Indeed, there seems to be a 
localization of fullerenes in the outer edges of the cell at later times (Figure 4, Figure 5), possibly 
indicating their imminent transport out of the cells. 
 
As mentioned above, the mitochondria is another organelle that is best known for its role in ROS 
production, which is a result of the electrochemical membrane potential (ΔΨm) across the inner 
mitochondrial membrane.21 We found sporadic localization of the C70-TR in the mitochondria at 
some of the times examined. Mitochondrial localization has been demonstrated before either 
directly or indirectly using other fullerene preparations.14, 16, 22, 23 Given that fullerenes are potent 
antioxidants that can react with ROS, it has been speculated that much of their inhibitory 
capabilities are linked to this radical-scavenging ability. However, we show here that fullerenes 
that are effective anti-inflammatory agents mainly target ER, which is also a ROS-producing 
organelle. It is possible the C70-TR may not reflect the same targeting specificity as the C70 
derivative without TR. We are currently engineering fullerenes without bulky side chains that are 
structurally the same as those described before, so that results obtained on inhibitory capabilities 
can be extrapolated to organelle targeting more specifically. 
 
In conclusion, we have identified the ER as a primary organelle for 70-carbon–based fullerene 
derivatives localization in human MCs as opposed to previous publications that show 60-carbon–
based fullerenes localize to the mitochondria This localization may help explain how the 
fullerenes exhibit their inhibitory activity through blunting of calcium and ROS spikes leading to 
subsequent reduction in histamine deganulation and cytokine production. Fullerenes are potent 
antioxidants and are being investigated as therapies for a wide range of diseases.24, 25, 26 This may 
have clinical implications for developing future fullerene-based compounds; our efforts are 
focused on developing these lead candidates into novel ways to treat those diseases associated 
with MC activation including asthma, arthritis, and anaphylaxis. 
 
Appendix A. Supplementary data 
 
Supplementary Figure 1. Synthesis of fullerene-Texas Red conjugates. C70 was sequentially 
derivatized at the two poles with one lipophilic and one hydrophilic group. Texas red was 
covalently conjugated to the polar pole of C70 through a short polyethylene glycol (PEG7) spacer 
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